1st line approval of immunotherapy in lung cancer

Since 01.02.2017 Keytruda® (Pembrolizumab) is approved as the first immunotherapy in the 1st line treatment of advanced lung cancer, which tumor cells express high levels of PD-L1. In the study immunotherapy was better than conventional chemotherapy in this subset of patients.

Further information